Pediatric Oncology

The OncLive Pediatric Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of cancers in pediatric patients, including acute lymphoblastic leukemia, acute myeloid leukemia, brain cancers, sarcomas, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in childhood and adolescent and young adult cancers.

Latest News

Burton Eliot Appel, MD, of Hackensack University Medical Center
International Childhood Cancer Day Shines a Spotlight on Challenges in Pediatric Oncology

February 20th 2024

Burton Eliot Appel, MD, discusses the importance of recognizing Childhood Cancer Day in pediatric patients with cancer.

Burton Eliot Appel, MD, of Hackensack University Medical Center and Jersey Shore University Medical Center
Insights Into Pediatric Oncology on Childhood Cancer Day: Advances, Challenges, and Survivorship

February 15th 2024

The FDA has approved eflornithine (Iwilfin) as a treatment to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who have achieved at least a partial response to prior multi-agent, multimodality therapy including anti-GD2 immunotherapy.
FDA Approves Eflornithine for Adult, Pediatric Patients With High-Risk Neuroblastoma

December 13th 2023

FDA Grants Priority Review to Tovorafenib in Pediatric Relapsed/Progressive Low-Grade Glioma

October 30th 2023

The FDA has granted accelerated approval to entrectinib (Rozlytrek) for pediatric patients aged older than 1 month with solid tumors that harbor a NTRK gene fusion without a known acquired resistance mutation, are metastatic, or where surgical resection is likely to result in severe morbidity, and have progressed after treatment or have no satisfactory standard therapy options.
FDA Expands Entrectinib Indication in Pediatric Patients With NTRK+ Solid Tumors

October 20th 2023

More News